BioAtla Stock (NASDAQ:BCAB)
Previous Close
$2.09
52W Range
$1.14 - $4.02
50D Avg
$1.87
200D Avg
$2.14
Market Cap
$96.67M
Avg Vol (3M)
$1.16M
Beta
1.04
Div Yield
-
BCAB Company Profile
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
OLMA | Olema Pharmaceuticals, Inc. |
NRIX | Nurix Therapeutics, Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
KYMR | Kymera Therapeutics, Inc. |
IKNA | Ikena Oncology, Inc. |
FHTX | Foghorn Therapeutics Inc. |
IPSC | Century Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ERAS | Erasca, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
PASG | Passage Bio, Inc. |
ANTX | AN2 Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
RZLT | Rezolute, Inc. |
ADAG | Adagene Inc. |
NAUT | Nautilus Biotechnology, Inc. |
STTK | Shattuck Labs, Inc. |